HLAG Kit ELISA

N° du produit ABIN2043001

Détail du produit HLAG Kit ELISA

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reactivité: Rat

Méthode de détection: Colorimetric

Type de méthode: Sandwich ELISA

Gamme de detection: 0.31-20 ng/mL

Seuil minimal de détection: 0.31 ng/mL

Application: ELISA

Marque: BioAssay™

Sensibilité: < 0.136 ng/mL

Information d'application

Plaque: Pre-coated

Protocole: Beta-2-Microglobulin (b2M) BioAssay-ELISA Kit (Rat) is a Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Beta-2-Microglobulin (b2M). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Beta-2-Microglobulin (b2M). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Beta-2-Microglobulin (b2M), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm±10nm. The concentration of Beta-2-Microglobulin (b2M) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Restrictions: For Research Use only

Stockage

Stock: 4 °C/-20 °C

Détail du antigène

Antigène: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Autre désignation: b2-Microglobulin (b2M) (HLAG Produits)

Synonymes: MHC-G Kit ELISA, B-F Kit ELISA, B-F-S04 Kit ELISA, B-F-S05 Kit ELISA, B-F-S06 Kit ELISA, B-F-S07 Kit ELISA, B-FI Kit ELISA, B-FIV Kit ELISA, BF2 Kit ELISA, BFa2 Kit ELISA, BFw-03 Kit ELISA, BFw-05 Kit ELISA, BFz-01 Kit ELISA, major histocompatibility complex, class I, G Kit ELISA, MHC BF1 class I Kit ELISA, HLA-G Kit ELISA, BF1 Kit ELISA

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints